search
Back to results

Marfan Syndrome Moderate Exercise Pilot

Primary Purpose

Marfan Syndrome

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Exercise Intervention Group
Sponsored by
Baylor College of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Marfan Syndrome focused on measuring Cardiovascular, Moderate Exercise, Physical Therapy

Eligibility Criteria

12 Years - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must be between the ages of 12-21
  • Diagnosis of Marfan Syndrome
  • Must not have other conditions that limit the patients ability to perform exercise

Exclusion Criteria:

  • Patients who have undergone aortic surgery
  • Patients with major congenital heart disease

Sites / Locations

  • Texas Children's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Exercise Intervention Group

Arm Description

Group of up to 20 patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.

Outcomes

Primary Outcome Measures

Maximum VO2
Maximum VO2 in ml/kg/minute will be collected via Exercise Stress Test. Range 30-85, higher is better.

Secondary Outcome Measures

Mean systolic blood pressure
mmHg, range 70-200, both low and high are abnormal, goal is age, sex and height-based, goal 10-50 percentile
Mean Diastolic blood pressure
mmHg, range 20-150, both low and high are abnormal, goal is age, sex and height-based, goal 10-50 percentile
Mean pulse pressure
mmHg, systolic blood pressure minus diastolic blood pressure, range 30-70 mmHg, goal is normal range for age and sex
Weight
kg, range 50-300kg, lower is better, excluding underweight patients
BMI
kg/m2, lower is better generally, excluding pts with BMI <5% for age
Left ventricular strain by cardiac MRI
Continuous measure derived from post-processing MRI
Right ventricular strain by cardiac MRI
Continuous measure derived from post-processing MRI
Aortic root strain
Continuous measure %, higher is less stiff, Range 0-40
Aortic Root Distensibility
×10-3 mm Hg-1, Continuous measure, range 0.1-10
Aortic Root β-Stiffness index
No units, Range 0.1-90
Maximum aortic root dimension
Measured in cm, range 1-8cm
Aortic root z-score
No units, based on body surface area published references, range -3 to 25
Aortic pulse wave velocity from MRI
meters/second, range 0-30
Pulse wave velocity derived from applanation tonometry
meters/second, range 0-30
Augmentation index
%, range 1-90
Manual muscle testing score
Grade 0-5, higher is better
Reactive hyperemia index
no units, 0-4 range, higher is worse
Visual analog assessment of pain
no units, scale from 0-6, 6 is worse
Single Leg Stance Test
seconds, higher is better
Single limb squat test score
seconds, higher is better
Star Excursion Balance Test
%, range 0-100, higher is better
6M Timed Hop Test
milliseconds, range 1 to infinity, lower is better
Scale for Child Anxiety Related Emotional Disorders (SCARED) (ages 12-18 y)
41 item scale, each with 3 point Likert scale, scale is summed, range 0-123, higher is worse
Quality of Life Scale (QOLS) (ages 19-21 y)
16 items, each with 7 point Likert, higher is worse
Pediatric Quality of Life Scale (PedsQL) scale scores
reported in 3 domains, each reported on Likert scale, scaled to 0-100 scale, lower is worse
Children's Depression Inventory (CDI) 2 (ages 12-18 y)
28-item assessment that yields a Total Score, 2 scale scores, and 4 subscale scores. For each item, respondent is presented with 3 choices that correspond to 3 levels of symptomatology: 0 (absence of symptoms), 1 (mild or probable symptom), or 2 (definite symptom). Lower is better
Depression, Anxiety, & Stress Scale (DASS) (ages 19-21 y)
set of 3 self-report scales. Each scale contains 14 items, each with a 4-point severity/frequency scale, higher is worse

Full Information

First Posted
April 23, 2020
Last Updated
August 9, 2023
Sponsor
Baylor College of Medicine
Collaborators
The Marfan Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04641325
Brief Title
Marfan Syndrome Moderate Exercise Pilot
Official Title
Evaluating the Effects of Moderate Physical Activity on Health and Well-being in Adolescents and Young Adults With Marfan Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
November 9, 2020 (Actual)
Primary Completion Date
October 30, 2022 (Actual)
Study Completion Date
December 20, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Baylor College of Medicine
Collaborators
The Marfan Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Marfan syndrome (MFS) affects multiple organ systems including the heart, bones, ligaments, and eyes, and is associated with significant risk of aortic dissection. Given limited evidence from in-vitro studies, and theoretical concerns, the majority of patients with MFS are restricted from certain physical activities. The lack of exercise and deconditioning have detrimental effects including increasing weakness, joint pain, decreased endurance, and depressive symptoms. Given the significant paucity of data currently existing on the effects of exercise in humans with MFS, and the recent, optimistic findings in rodent models, this pilot trial was established to assess the effects of moderated dynamic exercise in adolescents and young adults with MFS.
Detailed Description
Marfan syndrome (MFS) affects multiple organ systems including the heart, bones, ligaments, and eyes, and is associated with significant risk of aortic dissection. Given anecdotal reports of aortic dissection, limited evidence from in-vitro studies, and theoretical concerns, the majority of patients with MFS are restricted from certain physical activities, most commonly isometric exercise and contact sports. Published guidelines also suggest restriction from highly dynamic competitive sports. While clinicians may mean to restrict patients only from competitive sports, often children and families interpret this caution as applying to almost all exercise, resulting in a large number of patients with Marfan syndrome being sedentary. This lack of exercise and deconditioning likely have detrimental effects in increasing weakness and joint pain and decreasing endurance. Depressive symptoms are also not uncommon in Marfan syndrome, and may be triggered or exacerbated by guidance to acutely cease participation in sports at the time of diagnosis. To date, as far as the investigators are aware, there are no published controlled studies on the effects of dynamic exercise on human subjects. In 2017, Mas-Stachurska et al published a study suggesting that a moderate level of dynamic exercise mitigated progressive degradation of the cardiac structures typically seen in Marfan Syndrome in a rodent sample. This study suggests the possibility that the fears surrounding moderate exercise in humans may be unwarranted. In addition, this study suggests that moderate exercise may actually protect the aorta and myocardium, in addition to the numerous other physical and emotional benefits that have been shown to result from consistent exercise. The overall goal is to evaluate the effects of a moderate dynamic exercise program on measures of cardiovascular, muscular, and mental health in adolescents and young adults with Marfan syndrome. The investigators plan to perform a randomized pilot study to calculate effect estimates to perform a larger multi-center study. The objective is to 1) randomize 20 patients with Marfan syndrome age 12-21 years to current status (controls) versus a moderate dynamic exercise intervention, then 2) allow the control group patients to undergo the exercise intervention. The investigators will then compare outcomes between both the intervention and control groups, and between the baseline and post-intervention states. Specific outcome measures will include cardiovascular assessment: maximal oxygen uptake (max VO2), segmental and central aortic stiffness, ventricular mass and volume, and endothelial function, muscular/physical assessment: manual muscle testing (MMT), functional balance, and pain assessment, and quality of life/mental health assessment: health-related quality of life, depression and anxiety screening scales. The hypothesis is that the intervention of a moderate exercise program introduced by a licensed physical therapist will result in improvement in cardiovascular status, muscular health, and mental health without detrimental effects on the aortic wall.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Marfan Syndrome
Keywords
Cardiovascular, Moderate Exercise, Physical Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
The first part of trial was a Randomized Controlled Step-Wedge Pilot Trial as below 2 groups (Exercise Intervention Group and Current Care Group) The first phase of the study will maintain the Current Care Group as the control. At the end of the first phase, the Current Care Group will crossover and receive the Exercise Intervention as the second phase of the trial. With the COVID-19 pandemic causing delays in the study, and decreased enrollment and decreased access to MRI, the study was altered to a single group. comparing the same outcomes at baseline and after the intervention. This eliminates the blinding of the PI, but those interpreting the tests are still blinded.
Masking
None (Open Label)
Masking Description
The primary investigator and the co-PI (physical therapist) will know whether testing is at baseline or follow-up, but will not know the cardiovascular outcome measures. The cardiovascular outcomes assessor will be fully blinded.
Allocation
N/A
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercise Intervention Group
Arm Type
Experimental
Arm Description
Group of up to 20 patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
Intervention Type
Other
Intervention Name(s)
Exercise Intervention Group
Intervention Description
Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 8 weeks all patients will return for re-assessment.
Primary Outcome Measure Information:
Title
Maximum VO2
Description
Maximum VO2 in ml/kg/minute will be collected via Exercise Stress Test. Range 30-85, higher is better.
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Mean systolic blood pressure
Description
mmHg, range 70-200, both low and high are abnormal, goal is age, sex and height-based, goal 10-50 percentile
Time Frame
4 months
Title
Mean Diastolic blood pressure
Description
mmHg, range 20-150, both low and high are abnormal, goal is age, sex and height-based, goal 10-50 percentile
Time Frame
4 months
Title
Mean pulse pressure
Description
mmHg, systolic blood pressure minus diastolic blood pressure, range 30-70 mmHg, goal is normal range for age and sex
Time Frame
4 months
Title
Weight
Description
kg, range 50-300kg, lower is better, excluding underweight patients
Time Frame
4 months
Title
BMI
Description
kg/m2, lower is better generally, excluding pts with BMI <5% for age
Time Frame
4 months
Title
Left ventricular strain by cardiac MRI
Description
Continuous measure derived from post-processing MRI
Time Frame
4 months
Title
Right ventricular strain by cardiac MRI
Description
Continuous measure derived from post-processing MRI
Time Frame
4 months
Title
Aortic root strain
Description
Continuous measure %, higher is less stiff, Range 0-40
Time Frame
4 months
Title
Aortic Root Distensibility
Description
×10-3 mm Hg-1, Continuous measure, range 0.1-10
Time Frame
4 months
Title
Aortic Root β-Stiffness index
Description
No units, Range 0.1-90
Time Frame
4 months
Title
Maximum aortic root dimension
Description
Measured in cm, range 1-8cm
Time Frame
4 months
Title
Aortic root z-score
Description
No units, based on body surface area published references, range -3 to 25
Time Frame
4 months
Title
Aortic pulse wave velocity from MRI
Description
meters/second, range 0-30
Time Frame
4 months
Title
Pulse wave velocity derived from applanation tonometry
Description
meters/second, range 0-30
Time Frame
4 months
Title
Augmentation index
Description
%, range 1-90
Time Frame
4 months
Title
Manual muscle testing score
Description
Grade 0-5, higher is better
Time Frame
4 months
Title
Reactive hyperemia index
Description
no units, 0-4 range, higher is worse
Time Frame
4 months
Title
Visual analog assessment of pain
Description
no units, scale from 0-6, 6 is worse
Time Frame
4 months
Title
Single Leg Stance Test
Description
seconds, higher is better
Time Frame
4 months
Title
Single limb squat test score
Description
seconds, higher is better
Time Frame
4 months
Title
Star Excursion Balance Test
Description
%, range 0-100, higher is better
Time Frame
4 months
Title
6M Timed Hop Test
Description
milliseconds, range 1 to infinity, lower is better
Time Frame
4 months
Title
Scale for Child Anxiety Related Emotional Disorders (SCARED) (ages 12-18 y)
Description
41 item scale, each with 3 point Likert scale, scale is summed, range 0-123, higher is worse
Time Frame
4 months
Title
Quality of Life Scale (QOLS) (ages 19-21 y)
Description
16 items, each with 7 point Likert, higher is worse
Time Frame
4 months
Title
Pediatric Quality of Life Scale (PedsQL) scale scores
Description
reported in 3 domains, each reported on Likert scale, scaled to 0-100 scale, lower is worse
Time Frame
4 months
Title
Children's Depression Inventory (CDI) 2 (ages 12-18 y)
Description
28-item assessment that yields a Total Score, 2 scale scores, and 4 subscale scores. For each item, respondent is presented with 3 choices that correspond to 3 levels of symptomatology: 0 (absence of symptoms), 1 (mild or probable symptom), or 2 (definite symptom). Lower is better
Time Frame
4 months
Title
Depression, Anxiety, & Stress Scale (DASS) (ages 19-21 y)
Description
set of 3 self-report scales. Each scale contains 14 items, each with a 4-point severity/frequency scale, higher is worse
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be between the ages of 12-21 Diagnosis of Marfan Syndrome Must not have other conditions that limit the patients ability to perform exercise Exclusion Criteria: Patients who have undergone aortic surgery Patients with major congenital heart disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shaine A Morris, MD MPH
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Texas Children's Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Marfan Syndrome Moderate Exercise Pilot

We'll reach out to this number within 24 hrs